Supplemental Table 1 : Results of primary screens determined compounds that had significant inhibition (>20%) of RSK1 kinase activity. Shaded agents were also identified through ICM molecular docking of the Prestwick compounds to a homology model of RSK1 and were selected for validation in subsequent assays.
Supplemental Table 2 : Molecular docking supports the ability of drugs to block RSK1 in additional crystal structures. Binding models for the lead compounds in relationship to the RSK1 NTKD co-crystallized to staurosporine, and puravalnol A. The Glidescore and rank of the lead compounds in the Prestwick Library are also shown. Table 4 : Predicted binding of luteolin to 252 known drug targets. 3D structures from PDB were used to dock luteolin using Glide and ICM. Targets were ranked based on pfm filters and ICM score.
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